<DOC>
	<DOCNO>NCT02412735</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , double-blind , placebo-controlled Phase 3 study design evaluate safety efficacy Mesoblast 's rexlemestrocel-L alone combine hyaluronic acid ( HA ) subject chronic low back pain ( &gt; 6 month ) associate moderate radiographic degenerative change disc</brief_summary>
	<brief_title>A Prospective , Multicenter , Randomized , Double-blind , Placebo-controlled Study Evaluate Efficacy Safety Single Injection Rexlemestrocel-L Alone Combined With Hyaluronic Acid ( HA ) Subjects With Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Male female subject 18 year age old If female childbearing potential , subject nonpregnant , nonnursing , agree use highly effective method contraception minimum 24 month posttreatment Signed inform consent countryappropriate privacy form indicate subject willing undergo treatment willing available examination schedule study duration Have document diagnosis moderate radiographic degeneration intervertebral disc L1 S1 , disc suspect cause CLBP Chronic low back pain associate moderate radiographic degeneration lumbar disc define follow ( subject must meet listed condition ) : 1 . Chronic low back pain least 6 month 2 . Have fail 6 month conservative back pain care . ( Conservative treatment regimen may include follow : initial rest , medication [ e.g. , antiinflammatory , analgesic , narcotics/opioids , muscle relaxant ] , massage , acupuncture , chiropractic manipulation , activity modification , homedirected lumbar exercise program , noninvasive pain control treatments procedure ) 3 . Have minimum undergone supervise physical therapy , daily walk routine , therapeutic exercise , back education program specifically treatment low back pain AND take pain medication back pain ( e.g . NSAID and/or opioid medication ) . 4 . Change normal disc morphology index disc define radiographic evaluation core image evaluation provider . Radiographs must show following : A modified Pfirrmann score 3 , 4 , 5 6 MRI index disc Modic Grade II change less MRI index disc With without contain disc protrusion index disc MRI e. Low back pain least 40mm 90mm 100mm low back pain VAS ( average pain 24 hour ) f. Leg pain ≤20mm legs 100mm VAS scale g. ODI score least 30 90 100 point scale . Female subject pregnant nursing , woman plan become pregnant first 24 month posttreatment Extreme obesity , define NIH Clinical Guidelines Body Mass Index ( BMI &gt; 40 ) Have undergone surgical procedure ( e.g . discectomy , intradiscal electrothermal therapy , intradiscal radiofrequency , artificial disc replacement , interbody fusion ) disc index adjacent level Osteoporosis , define dualenergy Xray absorptiometry ( DEXA ) scan . A DEXA Tscore ≤ 2.5 exclude subject . Any lumbar intradiscal injection , include steroid , index adjacent disc prior treatment injection , exception follow injection perform least 2 week prior study treatment : 1 . Contrast medium ( discography diagnostic injection ) 2 . NSAIDs 3 . Nerveblocking anesthetic ( e.g. , lidocaine , bupivacaine ) 4 . Antibiotics 5 . Saline Have undergone procedure affect structure/biomechanics index disc level ( e.g. , posterolateral fusion ) Active malignancy tumor source symptom history malignancy within 5 year prior enrolment study Have recipient prior allogeneic stem cell/progenitor cell therapy indication autologous stem cell/progenitor cell therapy biological intervention repair index intervertebral disc An average baseline morphine equivalent dose ( MED ) &gt; 75mg/day determined ediary entry screen period Taking systemic immunosuppresants A medical condition , serious intercurrent illness , extenuate circumstance would preclude participation study potentially decrease survival interfere ambulation rehabilitation . Subjects involve spinal litigation , include workman 's compensation , unless litigation complete Are transient severe alcohol substance abuse problem Clinically significant nerve pain ( e.g. , chronic radiculopathy neuropathy ) Clinically significant sacroiliac joint pain Compressive pathology due stenosis disc protrusion MRI associate clinical symptom define leg pain VAS &gt; 20mm 100mm neurologic deficit neurologic exam Disc extrusion sequestration lumbar spine MRI determine radiographic core lab Modified Pfirrmann score 7 8 lumbar level ( L1S1 ) MRI evaluation determine radiographic core lab Symptomatic involvement one lumbar disc Symptomatic central vertebral canal stenosis define neurogenic claudication Spondylolisthesis retrolisthesis Grade 2 Spondylolysis index adjacent level ( ) Lumbar spondylitis undifferentiated spondyloarthropathy affect index disc Spinal deformity define lumbar scoliosis Cobb angle lumbar spine great 15 degree Any fracture spine index adjacent level heal , clinically compromised vertebral body index level due current past trauma Facet pain index level adjacent segment determine diagnostic medial branch block rule facet joint involvement . Full thickness annular tear index level determine free flow contrast medium annulus fibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Lumbar Back Pain</keyword>
	<keyword>Low back pain</keyword>
	<keyword>Back pain</keyword>
	<keyword>Degenerative Disc Disease</keyword>
	<keyword>Injection Degenerated Lumbar Disc</keyword>
	<keyword>Intervertebral Disc Degeneration</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neurologic Manifestations</keyword>
	<keyword>Pain</keyword>
	<keyword>Spinal Diseases</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Adult Stem Cells</keyword>
	<keyword>Allogeneic Mesenchymal Precursor cell ( MPCs )</keyword>
	<keyword>Mesoblast</keyword>
	<keyword>Hyaluronic Acid</keyword>
	<keyword>Pharmaceutical Solutions</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>rexlemestrocel-L</keyword>
	<keyword>Viscosupplements</keyword>
</DOC>